Rare Disease Biotech Sell Rating Maintained: Early Clinical Data Fails to Offset Flagship Drug Revenue Decline
Research Report
America's First Brain-Dedicated PET Scanning Clinics: A Turnaround Play for Chart-Savvy Investors?
Contributed Technical Analyst Opinion
Buy Rating Reaffirmed: ALTO-207 TRD Trial on Track
Research Report
Neuroscience Co. Enters Catalyst-Rich 2026 With Multiple Phase 2 Readouts and US$120M Financing
Research Report
Biotech Company Accelerates AI Detection Breakthrough Globally
Durham, NC Biopharma Co. Finds High-Growth Drug Opportunity
Life Sciences Firm Advances Massive US$2.4B Market Opportunity
An AI-Powered Doctor & Patient Platform: Why This North American Provider is Gaining Market Momentum
Contributed Technical Analyst Opinion
Technical Analyst Stewart Thomson explains why he likes Rocket Doctor AI Inc. (AIDR:CSE; TREIF:OTC; 939:FRA). Langhorne, PA Biotech Eyes Mid-2026 Molbreevi Launch
Research Report
H.C. Wainwright reiterated its rating and price target on Savara Inc. (SVRA:NASDAQ), citing a cleared regulatory path for Molbreevi with an August 22, 2026, PDUFA date, no planned FDA Advisory Committee, and accelerating commercial preparations targeting 1,700 accounts and 4,500 healthcare professionals ahead of a potential approval in the rare autoimmune PAP market. Bothell, WA Bio Co. Poised for 17-20% Revenue Growth in 2026 as Cell Therapy Market Expands
Research Report
BioLife Solutions Inc. (BLFS:NASDAQ) reported strong 2025 results. The company is now a pure-play cell processing business, expecting double-digit growth driven by expanding cell and gene therapy adoption, according to an H.C. Wainwright & Co. research note. A New Infection Control Platform Launched
Contributed Technical Analyst Opinion
John Newell of John Newell & Associates shares his thoughts on BioLargo Inc. (BLGO:OTCQX) to explain why he thinks the stock is a Speculative Buy. Analyst Maintains Spec Buy on Biotech After Interim SAT-3247 DMD Data
Research Report
Leede Financial maintained its rating on Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ), with a US$16.00 price target following updated interim Phase II SAT-3247 data from the TRAILHEAD trial in Duchenne muscular dystrophy. Cannabis Producer Moves to the TSX as Analyst Flags Major Expansion Potential
Cannara Biotech Inc. (LOVE:TSX; LOVFF:OTCQX; BCB0:FSE) began trading on the Toronto Stock Exchange on March 2 after graduating from the TSX Venture Exchange. Atrium Research initiated coverage with a BUY rating and CA$3.00 target, citing best-in-class EBITDA margins of 29%.Medical Co.'s TULSA-PRO Installed Base Growth and CAPTAIN Trial Data Could Accelerate Adoption in 2026"
Research Report
Leede Financial maintained its rating on Profound Medical Corp. (PROF:NASDAQ; PRN:TSX), citing strong TULSA-PRO capital sales, expanding installed base, and upcoming CAPTAIN trial results at EAU meeting as key catalysts. Target Raised on CA Pharma Co. as EBITDA Margins Sustain Upward Trajectory
Research Report
Leede Financial maintains its current rating on CareRx and raised its target price, following FQ425 results showing continued sequential improvement in EBITDA, margins, and operating cash flow. 
Streetwise Key Charts
